Holger Fritsch

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Hartmut Döhner, Michael Lübbert, Walter Fiedler et al. · Blood · 2014 · 227 citations · Full text

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

Patrick Schöffski, Ahmad Awada, Herlinde Dumez et al. · European Journal of Cancer · 2011 · 163 citations

Dose-escalation Study, Oncology, Medicine +7

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève et al. · European Journal of Cancer · 2010 · 109 citations

Oncology, Medicine, Pathology +9

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

Martin Sebastian, Martin Reck, Cornelius F. Waller et al. · Journal of Thoracic Oncology · 2010 · 109 citations · Full text

Bi 2536, Novel Plk-1 Inhibitor, Medicine +6

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Walter M. Stadler, David J. Vaughn, Guru Sonpavde et al. · Cancer · 2013 · 106 citations